Overview of enoxaparin in the treatment of deep vein thrombosis

American Journal of Managed Care

Volumn 6, Issue 20 SUPPL., 2000, Pages

  Deitcher, S R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

BLEEDING; BONE ATROPHY; CLINICAL TRIAL; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; LENGTH OF STAY; MORTALITY; PRIORITY JOURNAL; RECURRENT DISEASE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ENOXAPARIN; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MANAGED CARE PROGRAMS; META-ANALYSIS; RANDOMIZED CONTROLLED TRIALS; VENOUS THROMBOSIS;

EID: 0033664749     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (17)

1. Syndromes of thrombosis and hypercoagulability. Congenital and acquired causes of thrombosis
2. Anticoagulant drugs in the treatment of pulmonary embolism: A controlled trial
3. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis
4. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal vein thrombosis
5. The weight-based heparin dosing nomogram compared with a 'standard care' nomogram. A randomized controlled trial
6. Low molecular weight heparins
7. Tissue factor pathway inhibitor
8. Low molecular weight heparin
9. Low molecular weight heparin(s)
10. Subcutaneous vs. intravenous heparin in the treatment of deep venous thrombosis - A randomized clinical trial
11. Comparison of subcutaneous unfractionated heparin with a LMWH (Fragmin) in patients with venous thromboembolism and contraindications to coumadin
12. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: A meta-analysis
13. Treatment of deep venous thrombosis with low molecular weight heparins and unfractionated heparin in initial treatment of venous thrombosis: A meta-analysis
14. Low molecular weight heparins and unfractionated heparins in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis
15. Subcutaneous low molecular weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis
16. A comparison of low molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis